Summit Therapeutics Interest Expense Over Time
SMMT Stock | USD 19.00 0.58 3.15% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Summit Therapeutics Performance and Summit Therapeutics Correlation. Summit |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Summit Therapeutics. If investors know Summit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Summit Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.23) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.73) |
The market value of Summit Therapeutics PLC is measured differently than its book value, which is the value of Summit that is recorded on the company's balance sheet. Investors also form their own opinion of Summit Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Summit Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Summit Therapeutics' market value can be influenced by many factors that don't directly affect Summit Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Summit Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Summit Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Summit Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Interest Expense Analysis
Compare Summit Therapeutics PLC and related stocks such as Nkarta Inc, Cullinan Oncology LLC, and Kezar Life Sciences Interest Expense Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NKTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 472.8 K | 313 K | 2.1 M | 5.6 M | 6.4 M | 6.7 M |
CGEM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 888 K | 65.4 M | 562.4 M | 646.7 M | 679 M |
KZR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 M | 159 K | 1.2 M | 1.6 M | 1.6 M |
KRON | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 76 K | 3 K | 3.9 M | 1.7 M | 2.3 M | 9.2 M | 9.6 M |
ZVSA | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 516.5 K | 821.4 K | 427.5 K | 457 K | 444.5 K |
OCEA | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 691 | 622 | 676 |
ELEV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7 K | 479 K | 4.2 M | 4.4 M |
PHIO | 0.0 | 0.0 | 30 K | 24 K | 0.0 | 0.0 | 0.0 | 1000 | 0.0 | 0.0 | 0.0 | 9 K | 175 K | 201.2 K | 211.3 K |
SONN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5 M | 2.6 M | 2.5 M | 2.5 M | 2.5 M | 0.0 | 40.8 K | 2.5 M | 2.3 M | 2.4 M |
ATNF | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 185.1 K | 1.1 M | 1.1 M | 26.7 K | 44.83 | 42.59 |
CDIO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.7 M | 3.7 M |
Summit Therapeutics PLC and related stocks such as Nkarta Inc, Cullinan Oncology LLC, and Kezar Life Sciences Interest Expense description
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.My Equities
My Current Equities and Potential Positions
Summit Therapeutics PLC | SMMT |
Classification | Biotech |
Location | United Kingdom |
Exchange | NASDAQ Exchange |
USD 19.0
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.